|  |  |  |  |
| --- | --- | --- | --- |
| **Analysis of complete cases** | **Complete Data** | **At least one missing covariate** | **p-value** |
| N | 1000 | 726 |  |
| Age at Symptom Onset (mean (SD)) | 61.06 (12.18) | 60.31 (12.68) | 0.223 |
| Definite ALS per El Escorial Criteria (%) | 282 (28.2) | 215 ( 33.3) | 0.033 |
| Upright Forced Vital Capacity at Screening (mean (SD)) | 76.80 (24.27) | 77.28 (22.13) | 0.844 |
| ALSFRS-R at Screening (mean (SD)) | 36.05 (7.73) | 30.98 (11.51) | <0.001 |
| Bulbar Onset (%) | 259 (25.9) | 199 ( 29.4) | 0.133 |
| History of Riluzole Usage (%) | 794 (79.4) | 500 (68.9) | <0.001 |
| Male (%) | 597 (59.7) | 395 ( 58.3) | 0.615 |
| Delay between symptom onset and ALS diagnosis (mean (SD)) | 18.30 (23.72) | 18.30 (30.59) | 0.999 |

Supplementary Table 2: Analysis of covariates and missing data